AU657910B2 - Receptor directed-toxin conjugates - Google Patents

Receptor directed-toxin conjugates Download PDF

Info

Publication number: AU657910B2
Authority: AU; Australia
Prior art keywords: receptor; conjugate according; targeted toxin; targeted; toxin conjugate
Prior art date: 1990-07-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU80606/91A

Other languages

English (en)

Other versions

AU8060691A (en

Inventor

Ebo Sybren Bos

Hermanus Antonius Maria Verheul

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Akzo NV

Original Assignee

Akzo NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-05

Filing date

1991-06-21

Publication date

1995-03-30

1991-06-21 Application filed by Akzo NV filed Critical Akzo NV

1992-02-04 Publication of AU8060691A publication Critical patent/AU8060691A/en

1995-03-30 Application granted granted Critical

1995-03-30 Publication of AU657910B2 publication Critical patent/AU657910B2/en

2011-06-21 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

239000002596 immunotoxin Substances 0.000 title claims description 22
239000003053 toxin Substances 0.000 claims description 40
231100000765 toxin Toxicity 0.000 claims description 38
108700012359 toxins Proteins 0.000 claims description 38
210000004027 cell Anatomy 0.000 claims description 32
102000005962 receptors Human genes 0.000 claims description 24
108020003175 receptors Proteins 0.000 claims description 24
230000027455 binding Effects 0.000 claims description 19
239000003446 ligand Substances 0.000 claims description 16
102000000588 Interleukin-2 Human genes 0.000 claims description 15
108010002350 Interleukin-2 Proteins 0.000 claims description 15
239000012634 fragment Substances 0.000 claims description 14
102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 12
108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 12
IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 claims description 11
UDLWSISPUSEJTG-UHFFFAOYSA-N Verrucarin A Natural products CC1CCOC(=O)C=CCCC(=O)OC2CC3OC4C=C(C)CCC4(COC(=O)C1O)C2(C)C35CO5 UDLWSISPUSEJTG-UHFFFAOYSA-N 0.000 claims description 9
230000008685 targeting Effects 0.000 claims description 9
NLUGUZJQJYVUHS-IDXDZYHTSA-N verrucarin A Chemical compound C([C@@]12[C@@]3(C)[C@@]45CCC(C)=C[C@H]4O[C@@H]1C[C@H]3OC(=O)\C=C/C=C/C(=O)OCC[C@H]([C@@H](C(=O)OC5)O)C)O2 NLUGUZJQJYVUHS-IDXDZYHTSA-N 0.000 claims description 9
NLUGUZJQJYVUHS-UHFFFAOYSA-N verrucarina A Natural products C1OC(=O)C(O)C(C)CCOC(=O)C=CC=CC(=O)OC2CC3OC4C=C(C)CCC41C2(C)C31CO1 NLUGUZJQJYVUHS-UHFFFAOYSA-N 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 3
229930195731 calicheamicin Natural products 0.000 claims description 3
230000008878 coupling Effects 0.000 claims description 3
238000010168 coupling process Methods 0.000 claims description 3
238000005859 coupling reaction Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
125000006850 spacer group Chemical group 0.000 claims description 3
AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 claims description 2
AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 claims description 2
AFMYMMXSQGUCBK-UHFFFAOYSA-N Endynamicin A Natural products C1#CC=CC#CC2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3C34OC32C(C)C(C(O)=O)=C(OC)C41 AFMYMMXSQGUCBK-UHFFFAOYSA-N 0.000 claims description 2
231100000678 Mycotoxin Toxicity 0.000 claims description 2
NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 claims description 2
108091008874 T cell receptors Proteins 0.000 claims description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
AFMYMMXSQGUCBK-AKMKHHNQSA-N dynemicin a Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 claims description 2
239000002636 mycotoxin Substances 0.000 claims description 2
230000001850 reproductive effect Effects 0.000 claims description 2
239000002253 acid Substances 0.000 claims 1
150000007513 acids Chemical class 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 claims 1
PIKGDUXACSBRJF-RYPNDVFKSA-N deoxyverrucarol Chemical compound C([C@@]12[C@@]3(CC[C@H]1O[C@@H]1C=C(CC[C@@]13CO)C)C)O2 PIKGDUXACSBRJF-RYPNDVFKSA-N 0.000 claims 1
108091008039 hormone receptors Proteins 0.000 claims 1
239000000562 conjugate Substances 0.000 description 22
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
238000011534 incubation Methods 0.000 description 9
GOTYCQXAAKQUOD-VINXHBPISA-N (1R,3R,8R,12S,13R,18E,20E,24R,25S,26S)-12-hydroxy-5,13,25-trimethylspiro[2,10,16,23-tetraoxatetracyclo[22.2.1.03,8.08,25]heptacosa-4,18,20-triene-26,2'-oxirane]-6,11,17,22-tetrone Chemical compound C[C@@H]1CCOC(=O)/C=C/C=C/C(=O)O[C@@H]2C[C@@H]3[C@]4([C@]2([C@]5(CC(=O)C(=C[C@H]5O3)C)COC(=O)[C@H]1O)C)CO4 GOTYCQXAAKQUOD-VINXHBPISA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000004809 thin layer chromatography Methods 0.000 description 6
229930190906 verrucarin Natural products 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 5
102000004338 Transferrin Human genes 0.000 description 5
108090000901 Transferrin Proteins 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
239000012581 transferrin Substances 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
238000013459 approach Methods 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
238000000034 method Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
238000012360 testing method Methods 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000002332 leydig cell Anatomy 0.000 description 3
229960003604 testosterone Drugs 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
102000009024 Epidermal Growth Factor Human genes 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000000837 carbohydrate group Chemical group 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
-1 deoxyve.rucarol Chemical compound 0.000 description 2
239000003480 eluent Substances 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229960003339 sodium phosphate Drugs 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
235000011008 sodium phosphates Nutrition 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
DUMYQRXGUWONHC-UHFFFAOYSA-N 5,5-diphenyltetrazole Chemical compound C1=CC=CC=C1C1(C=2C=CC=CC=2)N=NN=N1 DUMYQRXGUWONHC-UHFFFAOYSA-N 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
102220582664 Astrocytic phosphoprotein PEA-15_N14R_mutation Human genes 0.000 description 1
241000283725 Bos Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000023108 LH Receptors Human genes 0.000 description 1
108010011942 LH Receptors Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
101710087249 Small toxin Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
238000001994 activation Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
210000004524 haematopoietic cell Anatomy 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940084986 human chorionic gonadotropin Drugs 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
235000008979 vitamin B4 Nutrition 0.000 description 1
239000011579 vitamin B4 Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AU80606/91A 1990-07-05 1991-06-21 Receptor directed-toxin conjugates Ceased AU657910B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP90201790		1990-07-05
EP90201790		1990-07-05
PCT/EP1991/001169 WO1992000762A1 (fr)	1990-07-05	1991-06-21	Conjugues de toxine destines a des recepteurs

Publications (2)

Publication Number	Publication Date
AU8060691A AU8060691A (en)	1992-02-04
AU657910B2 true AU657910B2 (en)	1995-03-30

Family

ID=8205057

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU80606/91A Ceased AU657910B2 (en)	1990-07-05	1991-06-21	Receptor directed-toxin conjugates

Country Status (7)

Country	Link
EP (1)	EP0537229A1 (fr)
JP (1)	JPH05508634A (fr)
AU (1)	AU657910B2 (fr)
CA (1)	CA2086679A1 (fr)
IE (1)	IE912167A1 (fr)
WO (1)	WO1992000762A1 (fr)
ZA (1)	ZA914933B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06508821A (ja) *	1991-03-07	1994-10-06	セラジュン　インク	ウイルス病治療のための細胞表面受容体を標的とする分子の使用
WO1993024135A1 (fr) *	1992-05-26	1993-12-09	Immunex Corporation	Nouvelle cytokine de fixation sur cd30
US5536642A (en) *	1993-09-09	1996-07-16	Barbera-Guillem; Emilio	Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
AU709988B2 (en) *	1995-06-07	1999-09-09	Innogenetics N.V.	Immunotoxins specific for CD80 and CD86 expressing cells
US6083477A (en)	1996-10-17	2000-07-04	Immunomedics, Inc.	Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
ATE424415T1 (de) *	1998-01-15	2009-03-15	Ct Molecular Med & Immunology	BISPEZIFISCHE ßTARGETING MOIETYß UMFASSEND EINEN ANTIKÖRPER GEGEN CEA (CARCINOEMBRYONIC ANTIGEN) UND DIE LIGANDEN-BINDENDE REGION DER IL13REZEPTOR ALPHA UNTEREINHEIT
US6703488B1 (en)	1998-01-15	2004-03-09	Center For Molecular Medicine And Immunology	Antibody/receptor targeting moiety for enhanced delivery of armed ligand
EA201690388A1 (ru)	2013-08-14	2016-07-29	Уильям Марш Райс Юниверсити	Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
KR20240135631A (ko) *	2022-01-14	2024-09-11	리제너론 파마슈티칼스 인코포레이티드	베루카린 a 유도체 및 이의 항체 약물 접합체

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU608531B2 (en) *	1986-08-07	1991-04-11	Battelle Memorial Institute	Advanced anticancer therapy and cytotoxic medicaments for its implementation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6408586A (en) *	1985-10-03	1987-04-24	Biotechnology Research Partners Limited	Novel lipoprotein-based drug-delivery systems
PT89121A (pt) *	1987-12-04	1989-12-29	Du Pont	Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
JPH03504248A (ja) *	1988-05-19	1991-09-19	ザ・ベス・イスラエル・ホスピタル・アソシエーション	外来抗原に対する寛容の誘発
EP0378666A4 (en) *	1988-07-05	1992-01-22	Amgen Inc.	Interleukin ii analogs
US5149782A (en) *	1988-08-19	1992-09-22	Tanox Biosystems, Inc.	Molecular conjugates containing cell membrane-blending agents

1991
- 1991-06-21 JP JP91511341A patent/JPH05508634A/ja active Pending
- 1991-06-21 IE IE216791A patent/IE912167A1/en unknown
- 1991-06-21 CA CA002086679A patent/CA2086679A1/fr not_active Abandoned
- 1991-06-21 AU AU80606/91A patent/AU657910B2/en not_active Ceased
- 1991-06-21 EP EP91912210A patent/EP0537229A1/fr not_active Withdrawn
- 1991-06-21 WO PCT/EP1991/001169 patent/WO1992000762A1/fr not_active Application Discontinuation
- 1991-06-26 ZA ZA914933A patent/ZA914933B/xx unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU608531B2 (en) *	1986-08-07	1991-04-11	Battelle Memorial Institute	Advanced anticancer therapy and cytotoxic medicaments for its implementation

Also Published As

Publication number	Publication date
IE912167A1 (en)	1992-01-15
JPH05508634A (ja)	1993-12-02
EP0537229A1 (fr)	1993-04-21
CA2086679A1 (fr)	1992-01-06
ZA914933B (en)	1992-04-29
AU8060691A (en)	1992-02-04
WO1992000762A1 (fr)	1992-01-23

Publication	Publication Date	Title
AU2020200975B2 (en)	2021-01-28	New stable antibody-drug conjugate, preparation method therefor, and use thereof
US5843903A (en)	1998-12-01	Targeted cytotoxic anthracycline analogs
DE69528523T2 (de)	2003-06-12	Rezeptor modulierendes mitteln und entsprechendes verfahren
US5280113A (en)	1994-01-18	Method for producing synthetic N-linked glycoconjugates
US6262253B1 (en)	2001-07-17	Vitamin B12 conjugates with gcsf, analogues thereof and pharmaceutical compositions
Kratz et al.	1999	Drug-polymer conjugates containing acid-cleavable bonds
CA2124329C (fr)	2008-11-18	Composes, compositions et methodes de fixation de substances bio-actives aux membranes de surface de bio-particules
US6709679B2 (en)	2004-03-23	Antineoplastic conjugates of transferin, albumin and polyethylene glycol
EP1198254B1 (fr)	2007-08-15	Conjugue excipient-produit pharmaceutique
US5840880A (en)	1998-11-24	Receptor modulating agents
AU657910B2 (en)	1995-03-30	Receptor directed-toxin conjugates
Smyth et al.	1986	Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies
US5869465A (en)	1999-02-09	Methods of receptor modulation and uses therefor
CA1330378C (fr)	1994-06-21	Derives amine d'analogues de l'acide folique
HK1007955A1 (en)	1999-04-30	Target specific antibody-superantigen conjugates and their preparation
HK1007955B (en)	1999-04-30	Target specific antibody-superantigen conjugates and their preparation
JPH03505576A (ja)	1991-12-05	有機化合物に関する改良
JPS60133367A (ja)	1985-07-16	リドカインおよびその類縁体のための免疫原
US5739287A (en)	1998-04-14	Biotinylated cobalamins
WO1997014711A1 (fr)	1997-04-24	Agents de modulation des recepteurs de la vitamine b¿12?
WO1997014711A9 (fr)	1997-10-02	Agents de modulation des recepteurs de la vitamine b¿12?
US5798097A (en)	1998-08-25	Immunogobulin conjugates
EP0476408A1 (fr)	1992-03-25	Conjugaison chimique de morpholino-anthracyclines avec des anticorps
Goerlach et al.	1991	In vitro antitumor activity of 2'-deoxy-5-fluorouridine-monoclonal antibody conjugates
DE69229356T2 (de)	1999-11-04	NEUE VERBESSERUNGEN hinsichtlich der RADIOMARKIERUNG von PROTEINEn

Legal Events

Date	Code	Title	Description
2000-02-03	MK14	Patent ceased section 143(a) (annual fees not paid) or expired